Why the study?
Does blood pressure lowering treatment reduce cardiovascular events differently across varying levels of baseline cardiovascular risk in hypertensive patients?
Does blood pressure lowering treatment reduce cardiovascular events differently across varying levels of baseline cardiovascular risk in hypertensive patients?
While absolute risk reduction from blood pressure lowering is greatest in high-risk patients, early treatment in low-to-moderate risk patients is necessary to prevent the high residual risk seen when treatment is delayed.
No takes yet. Share an insight, caveat, or question.
Greater absolute CV event reduction from BP lowering occurs at higher baseline risk; extends support for early treatment to limit residual risk in lower-risk patients.
Thomopoulos et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: